Cas:55290-52-3 2-Aminophenyl thiocyanate manufacturer & supplier

Chemical Name:2-Aminophenyl thiocyanate

CAS.NO:55290-52-3

Synonyms:Thiocyanic acid, 2-aminophenyl ester;Thiocyanic acid,2-aminophenyl ester (9CI);2-Aminophenyl thiocyanate

Molecular Formula:C₇H₆N₂S

Molecular Weight:150.201

HS Code:2930909090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:273.8±23.0 °C at 760 mmHg

Density:1.3±0.1 g/cm3

Index of Refraction:1.651

PSA:75.11000

Exact Mass:150.025162

LogP:1.34

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Thiocyanic acid, 2-aminophenyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Aminophenyl thiocyanate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Aminophenyl thiocyanate Use and application,2-Aminophenyl thiocyanate technical grade,usp/ep/jp grade.

Related News: Our quality control staff then conducts analyses in the testing laboratory to examine whether the API manufactured is ultrapure. 2-Aminophenyl thiocyanate manufacturer Alira is betting big on biometrics services by picking up Italy-based CROS NT, which has offices in Italy, London and North Carolina. The deal, for undisclosed terms, gives a boost to Alira’s direct clinical operations in Europe and access to biometrics services from the 29-year-old contract research organization. 2-Aminophenyl thiocyanate supplier Alira is betting big on biometrics services by picking up Italy-based CROS NT, which has offices in Italy, London and North Carolina. The deal, for undisclosed terms, gives a boost to Alira’s direct clinical operations in Europe and access to biometrics services from the 29-year-old contract research organization. 2-Aminophenyl thiocyanate vendor The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said. 2-Aminophenyl thiocyanate factory ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.